Lv4
564 积分 2023-10-13 加入
CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study
1小时前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
8天前
已完结
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
15天前
已完结
An Updated Understanding of Follicular Lymphoma Transformation
26天前
已完结
Follicular lymphoma
27天前
已完结
Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics
27天前
已完结
Frontline treatment of follicular lymphoma: What will it take to change current practice?
27天前
已完结
Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
28天前
已完结
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma
29天前
已完结
Building the Future Management of Follicular Lymphoma with T-Cell-Redirecting Strategies
29天前
已完结
皖公网安备34019202002308
